Park City Myeloma and Lymphoma Summit

Heber City, UT US
September 28, 2024

This CME-accredited activity, Park City Myeloma and Lymphoma Summit, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia.

This activity aims to improve learners' knowledge and competence to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical contexts and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Target Audience

  • Cancer care professionals

  • Practicing medical oncologists/hematologists

  • Radiation oncologists

  • Pathologists

  • Medical oncology and hematology fellows

  • Oncology nurses

  • Nurse practitioners

  • Physician assistants

  • Pharmacists

ORGANIZING COMMITTEE: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference  Co-Chairs:

Douglas Sborov, MD, MS - Huntsman Cancer Institute - Cancer Research North

Lindsey A. Fitzgerald, MD - Huntsman Cancer Institute - Cancer Research North

Bradley Hunter, MD, MPH - Intermountain Health LDS Hospital

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for induction and treatment for both transplant-eligible and transplant-ineligible with newly diagnosed multiple myeloma
  • Explain the management strategies for patients with 1-3 prior lines of therapy
  • Describe indications and safety of CAR-T, bispecific antibodies MM, and lymphoma
  • Interpret the evolving treatment strategies for the initial management of DLBCL

Parking

Parking is complimentary for all guests.

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 6.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.25 Contact Hours.
Course opens: 
05/17/2024
Course expires: 
12/31/2024
Event starts: 
09/28/2024 - 8:00am PDT
Event ends: 
09/28/2024 - 5:00pm PDT
Cost:
$150.00
Add to calendar: 

September 28th, 2024

All times are listed in Mountain Time (MT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits

08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:20 AM  Addressing Global Cancer Health Disparities - Building a 200-Bed Cancer Hospital In Nepal - Justin Marquart

08:20 AM – 09:50 AM  Session 1 - Multiple Myeloma (NDMM)

Session Chair: Douglas Sborov, MD, MS

08:20 AM – 08:30 AM  Introduction: The Brave New World of Multiple Myeloma - Douglas Sborov, MD, MS

08:30 AM – 09:00 AM  Newly Diagnosed Multiple Myeloma - Now We Know What We Thought We Knew - Dan Sherbenou, MD, PhD

09:00 AM – 09:10 AM  Debate: Velcade vs. Carfilzomib as the PI of Choice - Prashant Sharma, MD & Amandeep Godara, MBBS

09:10 AM – 09:20 AM  Debate: Autologous Transplant: Is There Still a Role? - Dane James Osborn, MD & Dan Sherbenou, MD, PhD

09:20 AM – 09:30 AM  Debate: Single Agent Lenalidomide vs. Doublet Maintenance - Brian McClune, DO & Saurabh Zanwar, MBBS, MD

09:30 AM – 09:40 AM  Data in Perspective - Ryan E. Wilcox, MD

09:40 AM – 09:50 AM  Q & A 

09:50 AM – 10:10 AM  Break & Exhibits

10:10 AM – 11:25 AM  Session 2 -  Multiple Myeloma (RRMM)

Session Chair:  Douglas Sborov, MD, MS

10:10 AM – 10:35 AM  Relapsed and Refractory Multiple Myeloma - Out with the Old, In with the New - Gliceida Galarza Fortuna, MD

10:35 AM – 10:45 AM  Debate: Early CAR-T or Wait Until Later? - Brian McClune, DO & Prashant Sharma, MD

10:45 AM – 10:55 AM  Debate: Bispecific or CAR-T First? -  Dane James Osborn, MD & Shashank Cingam, MD

10:55 AM – 11:05 AM  Debate: Reuse and Recycle - Saurabh Zanwar, MBBS, MD & Wayne D. Ormsby, MD

11:05 AM – 11:15 AM  Data in Perspective- Ryan E. Wilcox, MD

11:15 AM – 11:25 AM  Q & A 

11:25 PM – 12:25 PM  Session 3 - Lymphoma (CLL)

Session Chair: Allison M. Bock, MD

11:25 AM – 11:45 AM  Management in the Era of Targeted Therapies - Daniel A. Ermann, MD

11:45 AM – 11:55 AM  Debate: Acalabrutinib vs. Zanubrutinib - Boyu Hu, MD  & Daniel A. Ermann, MD

11:55 AM – 12:05 PM  Debate: 3L or Later?: Pirtobrutinib vs. CAR T-Cell - Deborah Stephens, DO  & Bradley Hunter, MD

12:05 PM – 12:15 PM  Data in Perspective - Rachel E. Hu, MD

12:15 PM – 12:25 PM  Q & A 

12:25 PM – 01:25 PM  Lunch & Exhibits

Product Theater Sponsored by Johnson & Johnson in Overlook Restaurant

Topic: What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma

Speaker: Daanish Hoda, MD

* This is a non-CME activity *

01:25 PM – 02:45 PM  Session 4 - Lymphoma (Novel Therapies in the Frontline Treatment of Lymphomas) 

Session Chair: Lindsey A. Fitzgerald, MD

01:25 PM – 01:30 PM  Introduction: Management of Lymphomas in the Era of Novel Therapies - Lindsey A. Fitzgerald, MD

01:30 PM – 01:55 PM  Novel Therapies in cHL (S1826 data), MCL (TRIANGLE, Boven), DLBCL (POLARIX) - Rachel E. Hu, MD

01:55 PM – 02:05 PM  Debate: Newer regimens: ANVD and BrECADD vs. Older regimens: AAVD and RATHL for Newly Diagnosed Advanced Stage cHL - Matthew Genyeh Mei, MD & Harsh Shah, DO

02:05 PM – 02:15 PM  Debate:  How Do We Use the TRIANGLE Study in MCL – Auto-Transplant vs. Not - Sagar S. Patel, MD & Michael Wang, MD

02:15 PM – 02:25 PM  Debate: PolaRCHP vs. RCHOP for Advanced Stage DLBCL - Lindsey A. Fitzgerald, MD & Daniel R. Sims, DO

02:25 PM – 02:35 PM  Data in Perspective - Xylina T. Gregg, MD

02:35 PM – 02:45 PM  Q & A 

02:45 PM – 03:00 PM  Break & Exhibits

03:00 PM – 04:15 PM  Session 5 - Lymphoma (Novel Therapies in Relapsed/Refractory Non Hodgkin Lymphomas) 

Session Chair: Bradley Hunter, MD

03:00 PM – 03:25 PM  Novel Therapies in Relapsed NHLs (CAR T, Bispecifics, Targeted Agents) -  Bradley Hunter, MD

03:25 PM – 03:35 PM  Debate: What First in Relapsed NHL – CAR T vs. Bispecific?- Joseph Maakaron, MD & Narendranath Epperla, MD, MS

03:35 PM – 03:45 PM  Debate: Glofitamab vs. Epcoritamab in Rel DLBCL - Ahmad S. Halwani, MD & Allison M. Bock, MD

03:45 PM – 03:55 PM  Debate: Best Targeted Regimen for LBCL Patients Ineligible for CAR T, AutoSCT – 2L Tafa/Len vs. Pola-BR -  Boyu Hu, MD & Charalambos (Babis) Andreadis, MD

03:55 PM – 04:05 PM  Data in Perspective - Stephen Spurgeon, MD

04:05 PM – 04:15 PM  Q & A

04:15 PM  Adjourn

Black Rock Mountain Resort
909 W Peace Tree Trail
Heber City, UT 84032
United States

 

Parking

Parking is complimentary for all guests.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Lindsey Fitzgerald, MD

has no relevant financial relationships to disclose at this time.

Bradley Hunter, MD. MPH

has a financial relationship (Professional Services) with Kite Pharma;.
has a financial relationship (Professional Services) with Notable Labs;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Novartis;.

Douglas Sborov, MD MS

has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with Arcellx;.
has a financial relationship (Professional Services) with Bioline;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Bristol Myer Squibb;.
has a financial relationship (Professional Services) with Genentech;.
Session Chair(s)

Allison Bock

has a financial relationship (Grant Or Contract) with Genmab/Abbvie;.
has a financial relationship (Travel) with Regeneron;.
has a financial relationship (Other) with Abbvie;.
Speaker/Topic Presenter(s)

Charalambos Andreadis, MD, MS

has a financial relationship (Independent contractor) with Roche;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Kite/Gilead;.
has a financial relationship (Independent contractor) with Pharmacyclics;.
has a financial relationship (Independent contractor) with Lilly;.

Allison Bock

has a financial relationship (Grant Or Contract) with Genmab/Abbvie;.
has a financial relationship (Travel) with Regeneron;.
has a financial relationship (Other) with Abbvie;.

Shashank Cingam

has no relevant financial relationships to disclose at this time.

Rachel E Hu

has no relevant financial relationships to disclose at this time.

Narendranath Epperla, MD, MS

has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Beigene;.
has a financial relationship (Other) with Lilly;.
has a financial relationship (Other) with Ipsen;.

Daniel Ermann, Medical Doctor

has no relevant financial relationships to disclose at this time.

Gliceida Galarza Fortuna

has no relevant financial relationships to disclose at this time.

Amandeep Godara, MD

has a financial relationship (Other) with Janssen;.

Xylina Gregg, MD

has no relevant financial relationships to disclose at this time.

Ahmad Halwani, M.D.

has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Abbvie/Pharmacyclics;.

Boyu Hu

has a financial relationship (Other) with ADC Therapeutics;.
has a financial relationship (Grant Or Contract) with Repare Therapeutics;.
has a financial relationship (Other) with ImmPACT Bio;.
has a financial relationship (Grant Or Contract) with Morphosys Ag;.
has a financial relationship (Grant Or Contract) with Artiva Biotherapeutics;.
has a financial relationship (Other) with Eli Lilly;.
has a financial relationship (Grant Or Contract) with CRISPR Therapeutics;.
has a financial relationship (Grant Or Contract) with Caribou Biosciences;.
has a financial relationship (Other) with GenMab;.
has a financial relationship (Grant Or Contract) with Celgene/BMS;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Other) with Seattle Genetics;.

Joseph Maakaron, MD

has no relevant financial relationships to disclose at this time.

Brian McClune, DO

has no relevant financial relationships to disclose at this time.

Matthew Mei, MD

has a financial relationship (Independent contractor) with Synethekine;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Other) with Beigene;.
has a financial relationship (Independent contractor) with ADC Therapeutics;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Independent contractor) with SeaGen;.

Wayne Ormsby, MD

has no relevant financial relationships to disclose at this time.

Dane Osborn, MD

has no relevant financial relationships to disclose at this time.

Sagar Patel, MD

has a financial relationship (Grant Or Contract) with Kite Pharma;.

Harsh Shah, D.O.

has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Epizyme;.
has a financial relationship (Grant Or Contract) with BeiGene;.

Prashant Sharma, MD, FACP

has no relevant financial relationships to disclose at this time.

Dan Sherbenou

has no relevant financial relationships to disclose at this time.

Dan Sims

has no relevant financial relationships to disclose at this time.

Stephen Spurgeon, MD

has a financial relationship (Grant Or Contract) with Schrodinger;.
has a financial relationship (Grant Or Contract) with BMS/Celgene;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Acerta;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Grant Or Contract) with Profound Bio;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Grant Or Contract) with Beigene;.

Debbie Stephens, DO

has a financial relationship (Grant Or Contract) with Abbvie, Genentech, AstraZeneca, Beigene, Novartis;.
has a financial relationship (Independent contractor) with Abbvie, AstraZeneca, Genentech, Beigene, BMS, Lilly, Pharmacyclics, Janssen;.

Michael Wang

has a financial relationship (Other) with Acerta Pharma;.
has a financial relationship (Professional Services) with AstraZeneca;.

Ryan Wilcox, MD

has no relevant financial relationships to disclose at this time.

Saurabh Zanwar, MBBS, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 6.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.25 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.